600079 Stock Overview
Researches, develops, produces, and sells pharmaceutical products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Humanwell Healthcare (Group) Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥23.93 |
| 52 Week High | CN¥25.98 |
| 52 Week Low | CN¥15.68 |
| Beta | 0.83 |
| 1 Month Change | 6.74% |
| 3 Month Change | 49.00% |
| 1 Year Change | -6.81% |
| 3 Year Change | 14.22% |
| 5 Year Change | 89.47% |
| Change since IPO | 1,303.10% |
Recent News & Updates
Investors Still Aren't Entirely Convinced By Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Earnings Despite 42% Price Jump
Oct 21
Is Humanwell Healthcare (Group)Ltd (SHSE:600079) Using Too Much Debt?
Sep 17Recent updates
Investors Still Aren't Entirely Convinced By Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Earnings Despite 42% Price Jump
Oct 21Is Humanwell Healthcare (Group)Ltd (SHSE:600079) Using Too Much Debt?
Sep 17There's No Escaping Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Muted Earnings Despite A 26% Share Price Rise
Aug 04Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement
May 22Shareholder Returns
| 600079 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.3% | -3.3% | -2.7% |
| 1Y | -6.8% | -3.1% | 11.8% |
Return vs Industry: 600079 underperformed the CN Pharmaceuticals industry which returned -3.1% over the past year.
Return vs Market: 600079 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 600079 volatility | |
|---|---|
| 600079 Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 600079 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600079's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 17,676 | Xiafei Deng | www.humanwell.com.cn |
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection for endotracheal intubation, and general anesthesia using artificial respiration; remifentanil hydrochloride for Injection for induction and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients requiring opioid analgesia; nabuphine hydrochloride injection for induction of anesthesia; alfentanil hydrochloride injection for general anesthesia induction; remimazolam besylate injection sedation for colonoscopy and bronchoscopy, and general anesthesia; and mifepristone preparations for termination of pregnancy or clinical remedial measures used to prevent pregnancy.
Humanwell Healthcare (Group) Co.,Ltd. Fundamentals Summary
| 600079 fundamental statistics | |
|---|---|
| Market cap | CN¥38.29b |
| Earnings (TTM) | CN¥1.96b |
| Revenue (TTM) | CN¥25.56b |
19.7x
P/E Ratio1.5x
P/S RatioIs 600079 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600079 income statement (TTM) | |
|---|---|
| Revenue | CN¥25.56b |
| Cost of Revenue | CN¥13.69b |
| Gross Profit | CN¥11.87b |
| Other Expenses | CN¥9.91b |
| Earnings | CN¥1.96b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.22 |
| Gross Margin | 46.44% |
| Net Profit Margin | 7.65% |
| Debt/Equity Ratio | 45.0% |
How did 600079 perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield50%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 13:11 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Humanwell Healthcare (Group) Co.,Ltd. is covered by 28 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| YANG QIAO | Changjiang Securities Co. LTD. |
| Pei Cheng | China Galaxy Securities Co., Ltd. |